share_log
Reuters ·  May 9 16:21
Oncternal Therapeutics- Cash, Cash Equivalents and Short-Term Investments Totaled $27.0 Mln as of March 31, 2024; Cash Runway Projected Into Q1 2025
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment